HPV in human cervical epithelium
HPV in human cervical epithelium A course of treatment with existing drugs prior to chemoradiation led to a 35% reduction in the risk of death or return of cancer, in trial results presented by researchers from UCL and UCLH. The INTERLACE phase III trial, funded by Cancer Research UK and UCL Cancer Trials Centre, assessed whether a short course of induction chemotherapy (IC) prior to chemoradiation (CRT) could reduce the rate of relapse and death among patients with locally advanced cervical cancer. As part of an analysis of clinical data, the preliminary results were presented at the European Society for Medical Oncology (ESMO) congress on Sunday 22 October 2023. The peak incidence of cervical cancer is in women in their early thirties, with around 3,200 new cases each year in the UK. CRT has been the standard treatment for cervical cancer since 1999, but despite improvements in radiation therapy techniques cancer returns in up to 30% of cases. The five-year survival rate for cervical cancer stands at around 70%. Over the course of 10 years, 500 patients took part in INTERLACE at hospitals in the UK, Mexico, India, Italy and Brazil.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
